Systems Pathology

Current and future research interests

The Wild laboratory is located at the University Hospital of Zurich. Among the main achievements of Peter Wild are that he has characterized the first mouse model of type II endometrial carcinomas, generated a seven-marker signature for clinical outcome in malignant melanoma, screened a library of small interfering RNAs for glycoproteome genes whose inhibition causes synthetic lethality with the PTEN gene in prostate cancer cells in vitro, and generated comprehensive cancer tissue microarrays of large patient cohorts with prostate, breast, bladder, and skin cancer. The laboratory is exceptionally well equipped with next-generation sequencing platforms (Ion Torrent Proton, Ion Torrent PGM, Roche 454 GS Junior), real-time cell viability assays, high-end fluorescence in situ hybridization (FISH) devices, and quantum dot techniques.

The research program is devoted to:
• the identification of clinically significant biomarkers for cancer and their implications for prognosis, therapy response, and classification of the disease,
• the implementation of novel molecular technologies in routine surgical pathology such as next-generation sequencing (NGS) or quantum dot fluorescence in situ hybridization (FISH) techniques, and
• the genetic dissection of the molecular and cellular mechanisms that underlie the malignant transformation of epithelial tissues with a current focus on prostate, urothelial and endometrial cancer.

Academic position & scientific background

Peter Wild is Senior Consultant and Assistant Professor (tenure track) for Systems Pathology at the University of Zurich (UZH) and University Hospital of Zurich (USZ). Peter Wild started as Assistant Professor in September 2012 and leads the High-Throughput Genomics Laboratory at the USZ. He is a graduate of the University of Regensburg Medical School in Germany, and has completed a postdoctoral training in Medical Biometrics at the University of Heidelberg, Germany. He has finished his doctoral thesis in Pathology (summa cum laude) in the laboratory of Ferdinand Hofstädter and Arndt Hartmann on predictive biomarkers of patients with advanced breast cancer in 2002 at the University Hospital Regensburg. For his residency training in Surgical Pathology, he went to the Institutes of Pathology at the University Hospitals in Regensburg, Hamburg-Eppendorf, and Zurich. In 2008 and 2010, he received the German and the Swiss Board Certification in Pathology, respectively. For a two year postdoctoral research training, he joined the laboratory of Wilhelm Krek at ETH Zurich to investigate the role of the PI3K-AKT-mTOR signalling pathway in cancer and its use for diagnostic serum signatures and functional studies (Cima I et al., PNAS 2011). Furthermore, he established and validated next-generation sequencing technologies at the Institute of Surgical Pathology, University of Zurich (Wild P et al., EMBO Mol Med 2012). In April 2010 he also received his Venia Legendi in Pathology from the University of Zurich for his work on molecular biomarkers of bladder cancer. Peter Wild has received several awards, including the Young Investigator Award for Cancer Research of the Charles Rodolphe Brupbacher Foundation in 2007 and the Research Award of the Novartis Foundation for Therapeutical Research in 2004.

Group members 
Prof. Dr. med. Peter Wild
UniversitätsSpital Zürich
Institut für Pathologie und Molekularpathologie
Schmelzbergstrasse 12
8091 Zürich
Tel +41 44 255 39 22


SysX.jpg       PhosphoNet_PPM_web.jpg

Zurich / Switzerland